Shield Therapeutics's total assets for Q4 2024 were £45.90M, an increase of 24.07% from the previous quarter. GB:STX total liabilities were £46.95M for the fiscal quarter, a 28.40% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.